PaxMedica, Inc.

PaxMedica, Inc. insiders are currently net buyers of PXMD stock, showing neutral sentiment over the past 90 days. Executives have purchased $997.5K while selling $529.1K, resulting in a positive net flow of $468.4K. This buying activity represents 65% of total transaction volume.

PaxMedica, Inc. has 9 active insiders who have filed SEC Form 4 transactions in the past 90 days. Michael Derby (Executive) leads with 13 transactions totaling $628.6K. Sciences Llc Tardimed (Executive) follows with 1 transactions worth $498.8K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. PaxMedica, Inc.'s current score of 65/100 indicates neutral insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $997.5K in purchases versus $529.1K in sales.

The most recent insider transaction occurred on Mar 12, 2024, when J. Casamento Charles (Executive) disposed of 992 shares at $0.69 per share for $684. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, PXMD insider trading sentiment is currently neutral with an Alignment Score of 65/100. The net insider flow of $468.4K reflects accumulation, with 65% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like PaxMedica, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At PXMD, we track all Form 4 filings—currently showing 86 transactions from 9 insiders over 90 days.

A 10b5-1 plan allows PaxMedica, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At PXMD, approximately 48% of recent transactions are 10b5-1 trades. This high percentage suggests much of the selling is routine and pre-planned.

You can monitor PaxMedica, Inc. (PXMD) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 9 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. PaxMedica, Inc.'s current score of 65/100 indicates moderately bullish sentiment suggesting insider confidence. This is calculated from $997.5K in purchases versus $529.1K in sales over 90 days, resulting in a net flow of $468.4K.

SEC Form 4 filings are mandatory reports that PaxMedica, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At PXMD, the most common type is "S" with 28 occurrences. The most recent Form 4 was filed on Mar 12, 2024 by J. Casamento Charles.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At PaxMedica, Inc., approximately 48% of recent transactions are executed under 10b5-1 plans, while 52% appear to be discretionary trades. This mix provides a balanced picture—some planned, others reflecting real-time decisions.